lorazepam has been researched along with Dementia Praecox in 54 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Acutely agitated patients with schizophrenia or schizoaffective disorder (n = 67) were randomized to receive 10 mg IM olanzapine (n = 37) or 5 mg IM haloperidol plus 2 mg IM lorazepam (n = 30)." | 9.20 | Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. ( Chen, HH; Chen, YH; Hsieh, MH; Huang, CL; Huang, GH; Hwang, TJ; Hwu, HG, 2015) |
| "The lorazepam-diazepam protocol can rapidly relieve retarded catatonia in schizophrenia." | 9.17 | Lorazepam-diazepam protocol for catatonia in schizophrenia: a 21-case analysis. ( Huang, TL; Lin, CC, 2013) |
| "Cognitive impairment causes morbidity in schizophrenia and could be due to abnormalities of cortical interneurons using the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)." | 9.12 | Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. ( Bullmore, E; Fletcher, P; Kamath, S; McKenna, P; Menzies, L; Ooi, C; Stephenson, C; Suckling, J, 2007) |
| "We conducted a prospective double-blind study of accelerated dose titration of olanzapine in the treatment of newly admitted acutely agitated patients with schizophrenia." | 9.11 | Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. ( Ahl, J; Kinon, BJ; McMullen, E; Rotelli, MD, 2004) |
| "The objective of this study was to estimate the effects of intramuscular haloperidol and lorazepam on the QT interval in volunteers with schizophrenia." | 9.11 | Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. ( Burke, M; Flockhart, D; Gorski, JC; Greenblatt, DJ; Harvey, AT; Preskorn, SH; Werder, S, 2004) |
| " The authors compared the efficacy and tolerability of ziprasidone and olanzapine in the treatment of acutely ill inpatients with schizophrenia or schizoaffective disorder." | 9.11 | Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. ( Glick, ID; Romano, SJ; Simpson, GM; Siu, CO; Weiden, PJ, 2004) |
| "Lorazepam was also given as needed (total dose, < or =4 mg/d) but not in place of a study drug dose increase." | 6.73 | Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. ( Chen, L; Kinon, BJ; Kollack-Walker, S; Sniadecki, J; Stauffer, VL, 2008) |
| " Acutely agitated patients with schizophrenia or schizoaffective disorder (n = 67) were randomized to receive 10 mg IM olanzapine (n = 37) or 5 mg IM haloperidol plus 2 mg IM lorazepam (n = 30)." | 5.20 | Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. ( Chen, HH; Chen, YH; Hsieh, MH; Huang, CL; Huang, GH; Hwang, TJ; Hwu, HG, 2015) |
| "The lorazepam-diazepam protocol can rapidly relieve retarded catatonia in schizophrenia." | 5.17 | Lorazepam-diazepam protocol for catatonia in schizophrenia: a 21-case analysis. ( Huang, TL; Lin, CC, 2013) |
| "Cognitive impairment causes morbidity in schizophrenia and could be due to abnormalities of cortical interneurons using the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)." | 5.12 | Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. ( Bullmore, E; Fletcher, P; Kamath, S; McKenna, P; Menzies, L; Ooi, C; Stephenson, C; Suckling, J, 2007) |
| "We conducted a prospective double-blind study of accelerated dose titration of olanzapine in the treatment of newly admitted acutely agitated patients with schizophrenia." | 5.11 | Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. ( Ahl, J; Kinon, BJ; McMullen, E; Rotelli, MD, 2004) |
| "The objective of this study was to estimate the effects of intramuscular haloperidol and lorazepam on the QT interval in volunteers with schizophrenia." | 5.11 | Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. ( Burke, M; Flockhart, D; Gorski, JC; Greenblatt, DJ; Harvey, AT; Preskorn, SH; Werder, S, 2004) |
| " The authors compared the efficacy and tolerability of ziprasidone and olanzapine in the treatment of acutely ill inpatients with schizophrenia or schizoaffective disorder." | 5.11 | Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. ( Glick, ID; Romano, SJ; Simpson, GM; Siu, CO; Weiden, PJ, 2004) |
| " In 3 double-blind studies, acutely agitated patients with schizophrenia (N = 311), bipolar mania (N = 201), or dementia (N = 206) were treated with intramuscular (1-3 injections/24 hrs) olanzapine (2." | 5.10 | Calming versus sedative effects of intramuscular olanzapine in agitated patients. ( Alaka, K; Battaglia, J; Lindborg, SR; Meehan, K; Wright, P, 2003) |
| "Over 67 days, 1,461 patients were screened in the ED, 269 had bipolar I or schizophrenia, 194 of whom had a contraindication to inhaled loxapine leaving 75 eligible patients; preconsent was obtained in 43 patients." | 3.91 | Study Enrollment When "Preconsent" Is Utilized for a Randomized Clinical Trial of Two Treatments for Acute Agitation in the Emergency Department. ( Cole, JB; Driver, BE; Klein, LR; Mullinax, SZ; Nordstrom, KD; Wilson, MP, 2019) |
| "The involvement of the gamma-aminobutyric acid (GABA) system in schizophrenia is suggested by postmortem studies and the common use of GABA receptor-potentiating agents in treatment." | 3.81 | Abnormal GABAergic function and face processing in schizophrenia: A pharmacologic-fMRI study. ( Fang, Y; Phan, KL; Taylor, SF; Tso, IF; Welsh, RC, 2015) |
| "Analysis 1 found that nonsedated patients with bipolar I disorder and schizophrenia showed significant decreases in PEC scores following treatment with aripiprazole IM (p < 0." | 3.74 | Intramuscular aripiprazole in the control of agitation. ( Citrome, LL; Crandall, DT; Currier, GW; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL, 2007) |
| " The concentration remained almost unaltered after 4 weeks of zuclopenthixol treatment in the schizophrenia group and following various neuroleptic, antidepressant, and anxiolytic medications in the nonschizophrenic patients despite a significant decrease of overt psychopathology assessed by the Brief Psychiatric Rating Scale." | 3.68 | Somatostatin in the cerebrospinal fluid of schizophrenic patients before and after neuroleptic drug treatment. ( Heikkilä, L, 1993) |
| "Lorazepam was also given as needed (total dose, < or =4 mg/d) but not in place of a study drug dose increase." | 2.73 | Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. ( Chen, L; Kinon, BJ; Kollack-Walker, S; Sniadecki, J; Stauffer, VL, 2008) |
| " Mean daily lorazepam dosage was 0." | 2.67 | Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis. ( Gaertner, HJ; Mahal, A; Stevens, A; Stevens, I, 1992) |
| "Catatonia is a clinical syndrome characterized by psychomotor disruption, which often goes undiagnosed." | 1.62 | Refractory catatonia in old age: a case report. ( Amin, J; Bean, E; Findlay, C; Gee, C, 2021) |
| "We recommend being alert for catatonia in patients with or without a psychiatric disorder." | 1.36 | [Catatonia]. ( Blom, JD; Bruijn, DJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (7.41) | 18.7374 |
| 1990's | 12 (22.22) | 18.2507 |
| 2000's | 16 (29.63) | 29.6817 |
| 2010's | 18 (33.33) | 24.3611 |
| 2020's | 4 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Spiegel, DR | 1 |
| Ayzman, A | 1 |
| Reid, FE | 1 |
| Ahuja, K | 1 |
| Worfolk, J | 1 |
| Ali, SA | 1 |
| Moyett, A | 1 |
| Argyelan, M | 1 |
| Barber, AD | 1 |
| Homan, P | 1 |
| Rubio, JM | 1 |
| Fales, C | 1 |
| Gallego, JA | 1 |
| Lencz, T | 1 |
| Malhotra, AK | 1 |
| Gouse, BM | 1 |
| Spears, WE | 1 |
| Nieves Archibald, A | 1 |
| Montalvo, C | 1 |
| Bean, E | 1 |
| Findlay, C | 1 |
| Gee, C | 1 |
| Amin, J | 1 |
| Kar, SK | 1 |
| Srivastava, A | 1 |
| Kathirvel, N | 1 |
| Ghosh, AK | 1 |
| Agrawal, AK | 1 |
| Das, S | 1 |
| Cevher Binici, N | 1 |
| Topal, Z | 1 |
| Demir Samurcu, N | 1 |
| Cansız, MA | 1 |
| Savcı, U | 1 |
| Öztürk, Y | 1 |
| Özyurt, G | 1 |
| Tufan, AE | 1 |
| Cole, JB | 1 |
| Klein, LR | 1 |
| Mullinax, SZ | 1 |
| Nordstrom, KD | 1 |
| Driver, BE | 1 |
| Wilson, MP | 1 |
| Lin, CC | 1 |
| Huang, TL | 1 |
| Taylor, SF | 2 |
| Demeter, E | 1 |
| Phan, KL | 2 |
| Tso, IF | 2 |
| Welsh, RC | 2 |
| Guru, S | 1 |
| Vanamoorthy, U | 1 |
| Loganathan, S | 1 |
| Varghese, M | 1 |
| Rausch, F | 1 |
| Mier, D | 1 |
| Eifler, S | 1 |
| Fenske, S | 1 |
| Schirmbeck, F | 1 |
| Englisch, S | 1 |
| Schilling, C | 1 |
| Meyer-Lindenberg, A | 2 |
| Kirsch, P | 1 |
| Zink, M | 1 |
| Huang, CL | 1 |
| Hwang, TJ | 1 |
| Chen, YH | 1 |
| Huang, GH | 1 |
| Hsieh, MH | 1 |
| Chen, HH | 1 |
| Hwu, HG | 1 |
| Fang, Y | 1 |
| Villamil, EA | 1 |
| Gonzalez, R | 1 |
| Kinon, BJ | 2 |
| Stauffer, VL | 1 |
| Kollack-Walker, S | 1 |
| Chen, L | 1 |
| Sniadecki, J | 1 |
| Dyer, C | 1 |
| Hoyer, C | 1 |
| Kranaster, L | 1 |
| Leweke, FM | 1 |
| Klosterkötter, J | 1 |
| Koethe, D | 1 |
| Zilles, D | 1 |
| Hasan, A | 1 |
| Gruber, O | 1 |
| Degner, D | 1 |
| Bruijn, DJ | 1 |
| Blom, JD | 1 |
| Coffey, MJ | 1 |
| Wang, BZ | 1 |
| Gupta, A | 1 |
| Bastiampillai, T | 1 |
| Sani, F | 1 |
| Battaglia, J | 2 |
| Lindborg, SR | 1 |
| Alaka, K | 1 |
| Meehan, K | 1 |
| Wright, P | 1 |
| Sielk, M | 1 |
| Lange, N | 1 |
| Ahl, J | 1 |
| Rotelli, MD | 1 |
| McMullen, E | 1 |
| Lejeune, J | 1 |
| Larmo, I | 1 |
| Chrzanowski, W | 1 |
| Witte, R | 1 |
| Karavatos, A | 1 |
| Schreiner, A | 1 |
| Lex, A | 1 |
| Medori, R | 2 |
| Harvey, AT | 1 |
| Flockhart, D | 1 |
| Gorski, JC | 1 |
| Greenblatt, DJ | 1 |
| Burke, M | 1 |
| Werder, S | 1 |
| Preskorn, SH | 1 |
| Härtter, S | 1 |
| Connemann, B | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Sachse, J | 1 |
| Hiemke, C | 1 |
| Simpson, GM | 1 |
| Glick, ID | 1 |
| Weiden, PJ | 1 |
| Romano, SJ | 1 |
| Siu, CO | 1 |
| Chakraborty, N | 1 |
| Johnston, T | 1 |
| Carnahan, RM | 1 |
| Perry, PJ | 1 |
| Mendhekar, DN | 1 |
| Jiloha, RC | 1 |
| Menzies, L | 1 |
| Ooi, C | 1 |
| Kamath, S | 1 |
| Suckling, J | 1 |
| McKenna, P | 1 |
| Fletcher, P | 1 |
| Bullmore, E | 1 |
| Stephenson, C | 1 |
| Currier, GW | 1 |
| Citrome, LL | 1 |
| Zimbroff, DL | 2 |
| Oren, D | 1 |
| Manos, G | 1 |
| McQuade, R | 1 |
| Pikalov, AA | 1 |
| Crandall, DT | 1 |
| Emsley, R | 1 |
| Koen, L | 1 |
| Oosthuizen, PP | 1 |
| Niehaus, DJ | 1 |
| Rabinowitz, J | 1 |
| Jaspert, A | 1 |
| Ebert, D | 1 |
| Bailine, SH | 1 |
| Safferman, A | 1 |
| Vital-Herne, J | 1 |
| Bernstein, S | 1 |
| Heikkilä, L | 1 |
| Northoff, G | 1 |
| Wenke, J | 1 |
| Demisch, L | 1 |
| Eckert, J | 1 |
| Gille, B | 1 |
| Pflug, B | 1 |
| Donnelly, CL | 1 |
| McEvoy, JP | 1 |
| Wilson, WH | 1 |
| Narasimhachari, N | 1 |
| Lee, JW | 1 |
| Schwartz, DL | 1 |
| Kramer, MS | 1 |
| Last, B | 1 |
| Getson, A | 1 |
| Reines, SA | 1 |
| Lane, HY | 1 |
| Su, KP | 1 |
| Chang, WH | 1 |
| Kanofsky, JD | 1 |
| Sandyk, R | 1 |
| Stevens, A | 1 |
| Stevens, I | 1 |
| Mahal, A | 1 |
| Gaertner, HJ | 1 |
| Gracia, RI | 1 |
| Gutierrez, JM | 1 |
| Faraone, SV | 1 |
| Tsuang, MT | 1 |
| Yassa, R | 1 |
| Nastase, C | 1 |
| Belzile, L | 1 |
| Adler, L | 1 |
| Angrist, B | 1 |
| Peselow, E | 1 |
| Corwin, J | 1 |
| Rotrosen, J | 1 |
| Chouinard, G | 1 |
| Fraser, AA | 1 |
| Ingram, IM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Observational Study of Anti-Psychotic Medication for the Treatment of Agitation in the Emergency Department[NCT02877108] | 100 participants (Anticipated) | Observational | 2016-04-30 | Recruiting | |||
| An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia[NCT00797277] | Phase 3 | 67 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Comparison of Oral Risperdal in Combination With Oral Lorazepam vs Standard Care Including Initial Conventional Neuroleptic IM Treatment, in Acute Schizophrenic Patients[NCT00249171] | Phase 4 | 226 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Agitation was further assessed by the Agitation Calmness Evaluation Scale (ACES) (Copyright 1998, Eli Lilly and Company), a single-item scale developed by Eli Lilly and Company on which 1 indicates marked agitation; 2, moderate agitation; 3, mild agitation; 4, normal; 5, mild calmness; 6, moderate calmness; 7, marked calmness; 8, deep sleep; and 9, unable to be aroused. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection
| Intervention | units on a scale (Mean) |
|---|---|
| 1. IM Olanzapine | 2.14 |
| 2. IM Haloperidol Pus Lorazepam | 2.23 |
The primary efficacy measure was PANSS-EC, which was derived from the PANSS by its originators using a principal-components factor analysis, and includes the items of tension, uncooperativeness, hostility, poor impulse control and excitement.22 The score of each item ranges from 1 (normal) to 7 (most severe), with a total sum score ranging from 5 to 35. The changes in PANSS-EC from baseline to 2 hours after the first injection were compared. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection
| Intervention | units on a scale (Mean) |
|---|---|
| 1. IM Olanzapine | -10.2 |
| 2. IM Haloperidol Plus Lorazepam | -9.9 |
2 reviews available for lorazepam and Dementia Praecox
| Article | Year |
|---|---|
[Problems with the treatment of schizophrenics in the doctor's office].
Topics: Acute Disease; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Diazepam; Drug Therapy, Combination | 2003 |
The treatment of acute agitation in schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Humans; Hypnotics and Sedatives; Lorazepam; Psychomotor Agitati | 2007 |
18 trials available for lorazepam and Dementia Praecox
| Article | Year |
|---|---|
Lorazepam-diazepam protocol for catatonia in schizophrenia: a 21-case analysis.
Topics: Anti-Anxiety Agents; Catatonia; Clinical Protocols; Diazepam; Drug Therapy, Combination; Humans; Lor | 2013 |
Abnormal GABAergic function and negative affect in schizophrenia.
Topics: Adult; Cerebral Cortex; Cross-Over Studies; Female; GABA Modulators; gamma-Aminobutyric Acid; Humans | 2014 |
Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Haloperidol; Humans | 2015 |
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Be | 2008 |
Calming versus sedative effects of intramuscular olanzapine in agitated patients.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dementia; Doubl | 2003 |
What can modern statistics offer imaging neuroscience?
Topics: Alzheimer Disease; Brain Mapping; GABA Modulators; Hippocampus; Humans; Lorazepam; Magnetic Resonanc | 2003 |
Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia.
Topics: Acute Disease; Administration, Oral; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepin | 2004 |
Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aggression; Antipsy | 2004 |
Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia.
Topics: Adult; Confidence Intervals; Cross-Over Studies; Electrocardiography; Female; Haloperidol; Humans; I | 2004 |
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administration S | 2004 |
Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia.
Topics: Adult; Brain; Cerebral Cortex; Cognition Disorders; Double-Blind Method; Flumazenil; GABA Modulators | 2007 |
Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study.
Topics: Adolescent; Adult; Antidepressive Agents; Blood Glucose; Body Mass Index; Cholesterol; Delayed-Actio | 2008 |
Catatonia: short-term response to lorazepam and dopaminergic metabolism.
Topics: Acute Disease; Adult; Anti-Anxiety Agents; Anxiety; Catatonia; Depressive Disorder; Dopamine; Dyskin | 1995 |
A study of the potential confounding effects of diet, caffeine, nicotine and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Diet; Drug Interactions; GABA Modulators; Homova | 1996 |
The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
Topics: Acute Disease; Adult; Antipsychotic Agents; Chloral Hydrate; Dopamine Antagonists; Double-Blind Meth | 1997 |
Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis.
Topics: Acute Disease; Adult; Drug Therapy, Combination; Female; Haloperidol; Humans; Lorazepam; Male; Middl | 1992 |
Efficacy of propranolol in neuroleptic-induced akathesia.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Chronic Disease; Female; Humans; Lorazepam; Ma | 1985 |
The use of benzodiazepines in the treatment of manic-depressive illness.
Topics: Acute Disease; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Basal Ga | 1988 |
34 other studies available for lorazepam and Dementia Praecox
| Article | Year |
|---|---|
Catatonic Coma in a Patient With Schizophrenia Receiving Palliative Care With Reversal of Symptoms With Lorazepam.
Topics: Catatonia; Coma; Humans; Lorazepam; Palliative Care; Schizophrenia | 2023 |
The effects of lorazepam on cortico-striatal connectivity in schizophrenia.
Topics: Brain Mapping; Corpus Striatum; Humans; Lorazepam; Magnetic Resonance Imaging; Neural Pathways; Schi | 2020 |
Catatonia in a hospitalized patient with COVID-19 and proposed immune-mediated mechanism.
Topics: Aged; Atrial Fibrillation; Basal Ganglia; Betacoronavirus; C-Reactive Protein; Catatonia; Coronaviru | 2020 |
Refractory catatonia in old age: a case report.
Topics: Aged; Benzodiazepines; Catatonia; Electroconvulsive Therapy; Humans; Lorazepam; Male; Schizophrenia | 2021 |
Attributions to new onset catatonic symptoms, late in the course of chronic schizophrenia.
Topics: Amlodipine; Antihypertensive Agents; Antipsychotic Agents; Aripiprazole; Catatonia; Chronic Disease; | 2017 |
Two unusual cases of protracted inter-ictal delirium following electroconvulsive therapy.
Topics: Adult; Antipsychotic Agents; Delirium; Electroconvulsive Therapy; Haloperidol; Humans; Lorazepam; Ma | 2017 |
The catatonic pupil: An unprivileged entity.
Topics: Adult; Antipsychotic Agents; Catatonia; Female; Humans; Lorazepam; Male; Psychotic Disorders; Pupil | 2018 |
Response of Catatonia to Amisulpride and Lorazepam in an Adolescent with Schizophenia.
Topics: Adolescent; Amisulpride; Anti-Anxiety Agents; Antipsychotic Agents; Catatonia; Humans; Lorazepam; Ma | 2018 |
Study Enrollment When "Preconsent" Is Utilized for a Randomized Clinical Trial of Two Treatments for Acute Agitation in the Emergency Department.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Emergency Service, Hospital; Ethics, Research; Female | 2019 |
Neuroleptic malignant syndrome following abrupt anti-cholinergic withdrawal: a case report.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Female; Humans; Lorazepam; Neuroleptic Malignant Synd | 2014 |
Reduced activation in the ventral striatum during probabilistic decision-making in patients in an at-risk mental state.
Topics: Antidepressive Agents; Brain Mapping; Cross-Sectional Studies; Decision Making; Female; Humans; Hypn | 2015 |
Abnormal GABAergic function and face processing in schizophrenia: A pharmacologic-fMRI study.
Topics: Adult; Brain; Face; Female; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives; Image Processi | 2015 |
Acute Urinary Retention and Catatonia in a Schizophrenic Male Patient.
Topics: Antipsychotic Agents; Catatonia; Diagnosis, Differential; GABA Modulators; Humans; Lorazepam; Male; | 2016 |
Psychiatrist accused of dishonesty for prescribing drugs to a patient under a false name.
Topics: Antipsychotic Agents; Deception; England; Female; Haloperidol; Humans; Lorazepam; Prescription Drugs | 2010 |
Familial differential treatment response in schizophrenia--lessons from a case of three affected siblings.
Topics: Adult; Amisulpride; Antipsychotic Agents; Dibenzothiazepines; Diseases in Twins; Female; Humans; Lor | 2010 |
Acute polydipsia and water intoxication in first episode schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dibenzothiazepines; Female; Humans; Hypnotics and Sedati | 2010 |
[Catatonia].
Topics: Adult; Catatonia; Female; Humans; Lorazepam; Male; Mental Disorders; Mood Disorders; Psychotic Disor | 2010 |
Catatonia and encephalopathy associated with paliperidone palmitate.
Topics: Aged; Antipsychotic Agents; Catatonia; Female; Humans; Isoxazoles; Lorazepam; Male; Neuroleptic Mali | 2012 |
Recurrent clozapine and lorazepam withdrawal psychosis with catatonia.
Topics: Adult; Antipsychotic Agents; Catatonia; Clozapine; Disease Management; Female; GABA Modulators; Huma | 2012 |
Elevated quetiapine serum concentrations in a patient treated concomitantly with doxepin, lorazepam, and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agen | 2004 |
Aripiprazole and neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Lorazepam; Male | 2004 |
Methodological concerns in a trial of ziprasidone and olanzapine.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bias; Dose-Response Relationship, Drug; | 2005 |
Neuroleptic malignant syndrome precipitated by haloperidol following clozapine discontinuation.
Topics: Adult; Anti-Anxiety Agents; Antiparkinson Agents; Antipsychotic Agents; Bromocriptine; Clozapine; Cr | 2005 |
Intramuscular aripiprazole in the control of agitation.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Arousal; Bipolar Disorder; Dose-Response Relationship, Dr | 2007 |
Switching patients from clozapine to risperidone therapy.
Topics: Antipsychotic Agents; Clonazepam; Clozapine; Drug Administration Schedule; Drug Therapy, Combination | 1995 |
[Benzodiazepine monotherapy in acute schizophrenia].
Topics: Acute Disease; Adult; Anti-Anxiety Agents; Diazepam; Humans; Lorazepam; Male; Schizophrenia; Schizop | 1994 |
Flumazenil reversal of benzodiazepine-induced sedation for a patient with severe pre-ECT anxiety.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Electroconvulsive Therapy; Flumazenil; Humans; Lorazepam; Male; | 1994 |
Somatostatin in the cerebrospinal fluid of schizophrenic patients before and after neuroleptic drug treatment.
Topics: Adult; Borderline Personality Disorder; Chronic Disease; Clopenthixol; Drug Therapy, Combination; Fe | 1993 |
Catatonia associated with hyponatremia.
Topics: Anti-Anxiety Agents; Catatonia; Humans; Hyponatremia; Lorazepam; Male; Middle Aged; Psychiatric Stat | 1997 |
Seizures after discontinuation of low-dose lorazepam from originally seizure-free clozapine regimen: combined effects?
Topics: Adult; Anti-Anxiety Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedul | 1999 |
Antioxidants in the treatment of schizophrenia.
Topics: Adult; Antioxidants; Ascorbic Acid; Brain; Drug Synergism; Drug Therapy, Combination; Free Radicals; | 1992 |
Use of lorazepam for increased anxiety after neuroleptic dose reduction.
Topics: Antipsychotic Agents; Anxiety; Combined Modality Therapy; Humans; Lorazepam; Male; Middle Aged; Schi | 1990 |
Lorazepam as an adjunct in the treatment of auditory hallucinations in a schizophrenic patient.
Topics: Aged; Chronic Disease; Female; Hallucinations; Humans; Lorazepam; Schizophrenia; Schizophrenic Psych | 1989 |
Lorazepam dependence and chronic psychosis.
Topics: Adult; Diagnosis, Differential; Humans; Lorazepam; Male; Psychoses, Substance-Induced; Schizophrenia | 1985 |